What are the new therapeutic interventions for an adult patient with established coronary artery disease?

New Therapeutic Interventions in Coronary Artery Disease

For adults with established coronary artery disease, the most impactful new interventions focus on aggressive lipid-lowering with combination therapy (including PCSK9 inhibitors and inclisiran), novel antidiabetic agents (SGLT2 inhibitors and GLP-1 receptor agonists) for cardioprotection, and selective use of anti-inflammatory therapy with colchicine. 1

Lipid-Lowering Therapy: The Foundation

Aggressive LDL-C Targets and Combination Therapy

• Target LDL-C <55 mg/dL (<1.4 mmol/L) or at least 50% reduction from baseline for patients with established CAD, representing a shift toward more aggressive lipid management 1

• Initiate high-intensity statins immediately (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) as first-line therapy 1

• Add ezetimibe within 4-6 weeks if LDL-C target not achieved, rather than waiting months—this combination can reduce LDL-C by up to 65% 1

• Consider upfront combination therapy (statin + ezetimibe) in patients with very high baseline LDL-C (>135 mg/dL) or those at extremely high risk, rather than sequential escalation 1

Novel PCSK9 Modulators

• PCSK9 inhibitors (evolocumab, alirocumab) provide additional 50-60% LDL-C reduction when added to statin therapy and reduce major adverse cardiovascular events 1

• Inclisiran represents a paradigm shift with twice-yearly subcutaneous injections (after initial dose and 3-month dose), achieving 60% LDL-C reduction and demonstrating 26% reduction in composite MACE in pooled analysis 1

• Bempedoic acid (180 mg daily) offers an alternative for statin-intolerant patients or as add-on therapy, reducing LDL-C by approximately 18-25% without increasing new-onset diabetes risk 1

Critical Implementation Point

The evidence strongly supports initiating PCSK9 inhibitors during hospitalization for acute coronary syndrome rather than waiting for outpatient titration, as this "earlier is better" approach maximizes benefit 1

Antidiabetic Agents with Cardiovascular Benefits

SGLT2 Inhibitors

• Recommended for patients with CAD and diabetes, heart failure, or chronic kidney disease regardless of glycemic control needs 1, 2

• Reduce cardiovascular death and heart failure hospitalizations by approximately 25-30% through mechanisms independent of glucose lowering 1, 2

• Specific agents with cardiovascular outcome data: empagliflozin, dapagliflozin, canagliflozin 1

GLP-1 Receptor Agonists

• Recommended for patients with CAD and diabetes, obesity (BMI ≥27), or established atherosclerotic disease 1, 2

• Reduce major adverse cardiovascular events by 12-14% and provide significant weight loss benefits (10-15% body weight reduction with newer agents) 1, 2

• Semaglutide and liraglutide have strongest cardiovascular outcome evidence in CAD populations 1, 2

Anti-Inflammatory Therapy

Colchicine

• Low-dose colchicine (0.5 mg daily) reduces recurrent cardiovascular events by targeting residual inflammatory risk in patients with established CAD 2, 3

• Demonstrated 23-31% reduction in composite cardiovascular outcomes in landmark trials (COLCOT, LoDoCo2) 2, 3

• Monitor for gastrointestinal side effects (diarrhea in 10-15% of patients) and avoid in severe renal or hepatic impairment 2, 3

Emerging Anti-Inflammatory Agents

• IL-1β inhibitors (canakinumab) showed proof-of-concept but cost-effectiveness remains a barrier to widespread adoption 3

Antiplatelet Therapy Updates

Dual Antiplatelet Therapy Duration

• For patients with ACS or PCI with stent placement, use dual antiplatelet therapy for 12 months with aspirin 75-100 mg plus either ticagrelor 90 mg twice daily, clopidogrel 75 mg daily, or prasugrel 10 mg daily 1

• After 12 months, transition to single antiplatelet therapy (aspirin 75-100 mg daily or clopidogrel 75 mg daily) for long-term secondary prevention 1

• Shorter durations (1-3 months) are safe in high bleeding risk patients with low-to-moderate ischemic risk 1

Important Caveats

• Prasugrel should be avoided in patients <60 kg body weight, age >75 years, or prior stroke/TIA due to increased bleeding risk without benefit 1

• Ticagrelor preferred over clopidogrel in ACS patients based on superior efficacy (16% relative risk reduction in cardiovascular death) 1

Revascularization Strategy Updates

PCI vs. Medical Therapy

• Medical therapy alone is non-inferior to routine revascularization in stable CAD without high-risk features, based on COURAGE and ISCHEMIA trials 2, 4

• FFR-guided PCI demonstrates long-term benefit over medical therapy alone in hemodynamically significant lesions (FFR ≤0.80), with 25% reduction in composite outcomes at 11 years primarily driven by reduced urgent revascularizations 4

Left Main Disease

• PCI with drug-eluting stents is now an acceptable alternative to CABG for selected patients with left main disease, particularly those with low anatomical complexity 1

Lifestyle and Risk Factor Management

Weight Management

• Target BMI 18.5-24.9 kg/m² through structured exercise and caloric restriction 1

• Intensify interventions when waist circumference ≥35 inches (women) or ≥40 inches (men) 1

• Initial weight loss goal of 5-10% from baseline with further reduction as tolerated 1

Diabetes Management

• Metformin remains first-line pharmacotherapy unless contraindicated 1

• Target HbA1c ≤7% in most patients, with less stringent goals for those with severe hypoglycemia history, limited life expectancy, or extensive comorbidities 1

What NOT to Use

Ineffective Interventions

• Fish oil/omega-3 supplements are NOT recommended as they provide no cardiovascular benefit in CAD patients 1

• Routine vitamin supplementation is NOT recommended for cardiovascular risk reduction 1

• Beta-blockers are NOT recommended long-term in stable CAD patients >1 year post-MI with preserved ejection fraction (>50%) and no other indication 1

• E-cigarettes are NOT recommended as first-line smoking cessation therapy due to lack of long-term safety data 1

Monitoring and Follow-Up

Lipid Monitoring

• Check lipid panel 4-6 weeks after initiating or intensifying therapy to assess target achievement 1

• Escalate therapy immediately if targets not met rather than waiting for next routine visit 1

Discharge Planning

• Standardized discharge letters should specify exact LDL-C targets (<55 mg/dL), escalation timelines (4-6 weeks), and specific next steps for primary care coordination 1

Common Pitfalls to Avoid

• Do not delay combination lipid therapy in patients with very high baseline LDL-C—upfront combination is more effective than sequential escalation 1

• Do not continue dual antiplatelet therapy indefinitely beyond 12 months in stable patients without specific high-risk features, as bleeding risk outweighs benefit 1

• Do not withhold SGLT2 inhibitors or GLP-1 agonists in non-diabetic CAD patients with heart failure or obesity—cardiovascular benefits extend beyond glycemic control 1, 2

• Do not perform routine stress testing in asymptomatic stable CAD patients without clinical change, as it does not improve outcomes and may lead to unnecessary procedures 1